Five-year net survival for the rare disease has doubled in recent years but more research is needed to better understand the condition, writes Michael McHale
While relatively uncommon, myelofibrosis patients thankfully face significantly better outcomes now than in years gone by.
A type of cancer that disrupts the body’s normal production of blood cells, myelofibrosis can cause extensive scarring in bone marrow, leading to severe anaemia that can cause weakness and fatigue.
A report on blood cancers published by the National Cancer Registry (NCR) in 2024 highlighted the prevalence of the disease. Between 2012 and 2021, 129 cases of primary myelofibrosis were…